Connect to other sites within the UBM Medica Network
Functional Status Affected Kidney Cancer Care, Survival
Patients with kidney cancer who are considered to be in poor functional health were less likely to receive cancer-directed surgery to treat their disease.
Active Surveillance May Be Possible for Some With Metastatic RCC
Certain patients with metastatic renal cell carcinoma safely underwent active surveillance of their disease prior to undergoing systemic therapy.
Complete Metastasectomy for Metastatic RCC Linked With Improved Survival
Undergoing complete metastasectomy for metastatic renal cell carcinoma was associated with improved survival outcomes, according to the results of a meta-analysis.
MicroRNAs Could Help Predict Response to TKIs for Metastatic RCC
A new study has found a series of potential microRNA biomarkers that could predict tyrosine kinase inhibitor response in RCC patients.
Survival Improves in African-American RCC Patients, but Disadvantage Persists
Both African-American and Caucasian patients with advanced RCC have seen improved survival with targeted therapies, though African-Americans still experience survival disadvantages.
Continuing Nivolumab After Progression Improves Survival in RCC
In this video we discuss the continuation of nivolumab after tumor progression in patients with advanced renal cell carcinoma in the CheckMate 025 trial.
Nivolumab Offers Long-Term Survival Benefit in Advanced RCC
Long-term follow-up of a phase I and a phase II study shows that nivolumab produces strong overall survival benefit in patients with advanced renal cell carcinoma.
Regimen Improved Survival in Children With High-Risk Wilms Tumors
In this video, Dr. Dix, discusses the results of two phase III trials that showed that in children with high-risk Wilms tumor, treatment with vincristine and dactinomycin plus the addition of doxorubicin improved outcomes.
Oncology Drug Snapshot: Axitinib (Inlyta)
This oncology drug snapshot takes a look at axitinib (Inlyta) for the treatment of advanced renal cell carcinoma (RCC) after failure of one prior systemic therapy.
By clicking Accept, you agree to become a member of the UBM Medica Community.